Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...
Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...
If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in ...
Zacks Investment Research on MSN
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients ...
Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
Vertex Pharmaceuticals (NASDAQ:VRTX) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...
One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. Where ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is the leading drugmaker in the treatment of cystic fibrosis, a life-threatening genetic disease that causes infections to several organs, including the lungs and ...
Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after the ...
Boston-based Vertex Pharmaceuticals is in a dispute with Canadian officials over access to its cystic fibrosis drugs, STAT reported. The dispute focuses on three of Vertex’s drugs, Kalydeco, Orkambi ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback